162 related articles for article (PubMed ID: 37041154)
1. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Bhatia V; Kamat NV; Pariva TE; Wu LT; Tsao A; Sasaki K; Sun H; Javier G; Nutt S; Coleman I; Hitchcock L; Zhang A; Rudoy D; Gulati R; Patel RA; Roudier MP; True LD; Srivastava S; Morrissey CM; Haffner MC; Nelson PS; Priceman SJ; Ishihara J; Lee JK
Nat Commun; 2023 Apr; 14(1):2041. PubMed ID: 37041154
[TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract][Full Text] [Related]
3. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer.
Jin Y; Lorvik KB; Jin Y; Beck C; Sike A; Persiconi I; Kvaløy E; Saatcioglu F; Dunn C; Kyte JA
Mol Ther Oncolytics; 2022 Sep; 26():189-206. PubMed ID: 35860008
[TBL] [Abstract][Full Text] [Related]
4. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
Zanvit P; van Dyk D; Fazenbaker C; McGlinchey K; Luo W; Pezold JM; Meekin J; Chang CY; Carrasco RA; Breen S; Cheung CS; Endlich-Frazier A; Clark B; Chu NJ; Vantellini A; Martin PL; Hoover CE; Riley K; Sweet SM; Chain D; Kim YJ; Tu E; Harder N; Phipps S; Damschroder M; Gilbreth RN; Cobbold M; Moody G; Bosco EE
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37966111
[TBL] [Abstract][Full Text] [Related]
6. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
7. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.
Lin TY; Park JA; Long A; Guo HF; Cheung NV
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34497115
[TBL] [Abstract][Full Text] [Related]
8. STEAP1 is overexpressed in cancers: a promising therapeutic target.
Moreaux J; Kassambara A; Hose D; Klein B
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):148-55. PubMed ID: 23142226
[TBL] [Abstract][Full Text] [Related]
9. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
10. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
11. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
12. Six transmembrane epithelial antigen of the prostate 1 is down-regulated by sex hormones in prostate cells.
Gomes IM; Santos CR; Socorro S; Maia CJ
Prostate; 2013 May; 73(6):605-13. PubMed ID: 23060075
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
14. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs.
Zhang X; Sun S; Miao Y; Yuan Y; Zhao W; Li H; Wei X; Huang C; Hu X; Wang B; Xu H; Zhang W; Gao X; Song J; Zheng J; Zhang Q
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3511-3520. PubMed ID: 35962287
[TBL] [Abstract][Full Text] [Related]
16. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.
Doran MG; Watson PA; Cheal SM; Spratt DE; Wongvipat J; Steckler JM; Carrasquillo JA; Evans MJ; Lewis JS
J Nucl Med; 2014 Dec; 55(12):2045-9. PubMed ID: 25453051
[TBL] [Abstract][Full Text] [Related]
17. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
18. Targeting STEAP1 as an anticancer strategy.
Nakamura H; Arihara Y; Takada K
Front Oncol; 2023; 13():1285661. PubMed ID: 37909017
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1
Chen X; Wang R; Chen A; Wang Y; Wang Y; Zhou J; Cao R
Biomed Pharmacother; 2019 Mar; 111():1124-1131. PubMed ID: 30841425
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.
Gomes IM; Rocha SM; Gaspar C; Alvelos MI; Santos CR; Socorro S; Maia CJ
Med Oncol; 2018 Feb; 35(3):40. PubMed ID: 29464393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]